GlassScriptPhysician profile
Laura Parks
NPI 1457507592
$15,712.31
in general payments reported to CMS, 2019-2025
33 companies · $2,969 in 2025
The $2,969 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,472 · 2021: $1,758 · 2022: $2,271 · 2023: $2,600 · 2024: $2,944 · 2025: $2,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,512.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,307.14 | 2019-2025 | |
| Amgen INC. | $1,976.22 | 2019-2025 | Enbrel, Otezla, Otezla |
| Ucb, INC. | $1,409.11 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,400.23 | 2019-2025 | |
| Janssen Biotech, INC. | $1,066.38 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $1,026.25 | 2019-2025 | Orencia |
| Pfizer INC. | $885.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $813.69 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $772.93 | 2020-2025 | Acthar |
| Lilly USA, LLC | $363.98 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $357.34 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $283.70 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $233.96 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.47 | 2020-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $199.76 | 2021-2025 | Saphnelo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $176.42 | 2019-2025 | Gazyva, Actemra |
| Sobi, INC | $159.64 | 2020-2025 | |
| Organon LLC | $135.11 | 2024-2025 | Hadlima, Nexplanon |
| Pacira Therapeutics, INC. | $124.22 | 2020-2021 | |
| Medexus Pharma, INC. | $117.33 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $106.64 | 2023-2024 | Idacio |
| Genzyme Corporation | $97.44 | 2025 | |
| Sandoz INC. | $90.77 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $69.87 | 2023-2025 | Strensiq |
| Horizon Therapeutics Plc | $68.24 | 2020-2022 | |
| Celgene Corporation | $63.89 | 2019 | |
| Mallinckrodt Enterprises LLC | $42.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $36.75 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $32.57 | 2024-2025 | Zilretta, Iovera |
| Kyowa Kirin, INC. | $21.86 | 2024 | Crysvita |
| Hikma Pharmaceuticals USA | $21.11 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.43 | 2022 | |
| Medtronic, INC. | $17.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.